New Intervention Priority Score in Elsevier's MTM 360 to Enhance Medicare Medication Therapy Management Efforts

ORLANDO, Florida, March 30, 2010 /PRNewswire-FirstCall/ -- Elsevier Clinical Decision Support, a leading provider of medical information and solutions, announced today that it has developed a quantitative ranking system that enables health plans to better control their medication therapy management (MTM) programs for Medicare Part D members.

The Intervention Priority Score (IPS) is a new feature of Elsevier's MTM 360, which is powered by the award-winning, highly accurate modeling technology of MEDai, an Elsevier company. Elsevier and MEDai developed the IPS specifically for health plans seeking to improve their management of MTM programs for their Medicare Part D business.

The new IPS is embedded in MTM 360 and will enable Medicare Part D sponsors to select members based on a priority ranking of intervention need. MTM 360 also addresses the CMS requirement to assign priority to health plan members who have requested a Comprehensive Medication Review, so those members are moved to the top of the list.

"Medication Therapy Management is an effective component in the management of multiple chronic conditions," said Swati Abbott, President and CEO of MEDai. "The development of our Intervention Priority Score allows health plans to intervene with patients based on a priority ranking that is determined by applying our modeling technology to patient-specific information like pharmacy and demographic data. By leveraging the IPS score, sponsors will be able to target the right members for inclusion in their MTM program and proactively intervene on those cases with the highest risk and greatest chance of having an adverse outcome."

MTM 360 was designed to facilitate the collection, documentation, analysis and reporting of data required as part of CMS's MTM program protocols. The solution allows clients to not only select eligible beneficiaries for MTM using CMS rules but also to create specific criteria that align with other initiatives their organizations are currently involved in. MTM 360 allows users to identify, stratify and monitor patient populations to ensure effective and efficient resource allocation. The program also supplies customizable documentation, communication, and reporting to streamline the MTM delivery process.

Elsevier's MTM 360 leverages MEDai's modeling technology which is recognized globally as being the most accurate. Its technology has consistently yielded the highest accuracy available as evidenced by their performance in The Association for Computing Machinery's Knowledge Discovery and Data Mining (ACM KDD) competition, as well as in the German Classification Society competition, also known as the GFKL, and additionally in a study conducted by Society of Actuaries.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com) and Cell (http://www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (http://www.sciencedirect.com), Scopus (http://www.scopus.com), Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and Nursing Consult (http://www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com) and MEDai's Pinpoint Review (http://www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (http://www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About MEDai

MEDai, Inc. is a subsidiary of Elsevier that offers award-winning solutions for the improvement of healthcare delivery. Utilizing cutting-edge technology, payors and care management organizations are able to predict patients at risk, identify cost drivers for their high-risk population, forecast future health plan costs, evaluate patient patterns over time and improve outcomes. For more information on MEDai, visit http://www.medai.com.

    Tom Reller
    Vice President, Global Corporate Relations
    +1-215-239-3508
    [email protected]

SOURCE Elsevier